Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

C/EBPβ Cooperates With MYB to Maintain the Oncogenic Program of AML Cells

News

November 13, 2023
PRESS RELEASE: on March 11, 2023, a new editorial perspective was published in Oncotarget, entitled, “C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells.” continue reading »

Combined Inhibition of SHP2 and Mutated RTKs Prevent Acquired Resistance in Leukemia

News

November 8, 2023
PRESS RELEASE: On March 31, 2023, a new editorial was published in Oncotarget, entitled, “Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors.” continue reading »

The Uncharted Role of HER2 Mutant Alleles in Breast Cancer

News

November 6, 2023
PRESS RELEASE: On October 31, 2023, a new editorial was published in Oncotarget, entitled, “The uncharted role of HER2 mutant alleles in breast cancer.” continue reading »

p53’s Protective Role in Extrahepatic Biliary Precancerous Lesions

Oncotarget

November 2, 2023
In this editorial, researchers from Japan discuss their recent study investigating the role of p53 in preventing the development of extrahepatic biliary cancer. continue reading »

FAAH Inhibition Ameliorates Murine Breast Cancer

News

November 1, 2023
PRESS RELEASE: On October 31, 2023, a new research paper was published in Oncotarget, entitled, “FAAH inhibition ameliorates breast cancer in a murine model.” continue reading »